Clinical trials: ICC
Intrahepatic Cholangiocarcinoma
HAIC With FOLFOX Versus Systemic Chemotherapy With GP for Unresectable ICC
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, 5-fluorouracil and leucovorin compared systemic chemotherapy of gemcitabine and cisplatin in…
- Trial name
- NCT04961970
- Testing
- oxaliplatin , fluorouracil, and leucovorin, gemcitabine and cisplatin
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Shi Ming
Intrahepatic Cholangiocarcinoma
Safety and Efficacy Evaluation of MUC-1 CART in the Treatment of Intrahepatic Cholangiocarcinoma
Intrahepatic cholangiocarcinoma (ICC) is one of the most common liver malignancies. Surgical treatment is the first choice. However, for patients without surgical indications, the benefits of conventional chemoradiotherapy are…
- Trial name
- NCT03633773
- Testing
- MUC-1 CART cell immunotherapy
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
ICC, Advanced Cancer
HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICC
Intrahepatic cholangiocarcinoma (ICC) has a poor prognosis. The aim of this study is to investigate the efficacy and safety of GP-HAIC combined with immunosuppressants in the treatment of initially unresectable ICC patients, as…
- Trial name
- Lalo (NCT07364305)
- Testing
- PD-L1 inhibitor, HAIC
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Unresectable Intrahepatic Cholangiocarcinoma
A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma
The study will be a single-center, single-arm, Phase II study of gemcitabine and cisplatin in combination with conventional trans-arterial chemoembolization therapy in adult patients with advanced ICC.
- Trial name
- NCT02994251
- Testing
- gemcitabine, Cisplatin, Conventional TACE (transarterial chemoembolization) with Doxorubicin/Mitomycin-C
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Yale University
Bile Duct Obstruction, Extrahepatic
Clinical Validation of an Immunocytochemistry Method Using MARS1
The sensitivity of brushing cytology used to distinguish the cause of biliary strictures is low and clinical usefulness is not secured.
- Trial name
- MARS1 (NCT04759794)
- Testing
- Cytology staining
- Where
- 5 sites in South Korea
- Volunteers
- 55 people
- Sponsor
- Gangnam Severance Hospital
Intrahepatic Cholangiocarcinoma (Icc)
Liquid Biopsy Using Exosomal miRNA Enables Risk Stratification of Potential Metastasis in Patients With Intrahepatic Cholangiocarcinoma.
Occult metastasis at the time of surgery is a major driver of poor outcomes in intrahepatic cholangiocarcinoma (ICC), yet reliable preoperative biomarkers to identify such patients are lacking.
- Trial name
- EXOMIC (NCT07224737)
- Testing
- EXOMIC small RNA sequencing, EXOMIC assay (qRT-PCR validation)
- Where
- United States
- Volunteers
- 230 people
- Sponsor
- City of Hope Medical Center
ICC
Combining Chemoradiotherapy With Sintilimab in First-Line ICC
To evaluate the effectiveness and safety of GC (gemcitabine + cisplatin) and radiotherapy combined with slulimumab in the treatment of first-line intrahepatic cholangiocarcinoma patients
- Trial name
- NCT06447454
- Testing
- radiotherapy, gemcitabine + cisplatin, slulimumab
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Shanghai Zhongshan Hospital
Postoperative Analgesia
Study of Postoperative ICC Analgesia
This study is to examine the analgesic effectiveness of continuous loco-regional analgesic application (ropivacaine) through surgically placed Intercostal Catheter (ICC) and to establish correctly this method as a possible…
- Trial name
- SPICA (NCT04939545)
- Testing
- Ropivacain, NaCl 0.9%
- Where
- Switzerland
- Volunteers
- 32 people
- Sponsor
- University Hospital, Basel, Switzerland
Combined Hepatocellular-cholangiocarcinoma, Combined Hepatocellular Carcinoma and Cholangiocarcinoma
Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data
This study focused on exploring new comprehensive treatment strategies for patients with unresectable combined hepatocellular-cholangiocarcinoma, classifying patients with CHC subtypes based on the combination of artificial…
- Conditions
- Combined Hepatocellular-cholangiocarcinoma, Combined Hepatocellular Carcinoma and Cholangiocarcinoma, Combined Hepatocellular and Cholangiocarcinoma
- Trial name
- NCT06849180
- Testing
- Interventional therapies combined with or without systemic drugs
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Zhongda Hospital
Intrahepatic Cholangiocarcinoma, Peripheral Cholangiocarcinoma
Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma
This is a Phase I study, which means we want to find out what effects, good and/or bad, this combination of drugs may have on the patient and the liver cancer at different dose levels.
- Conditions
- Intrahepatic Cholangiocarcinoma, Peripheral Cholangiocarcinoma, Cholangiolar Carcinoma, Cholangiocellular Carcinoma) (ICC)
- Trial name
- NCT01938729
- Testing
- Liver resection and placement of hepatic artery infusion pump, FLOXURIDINE, DEXAMETHASONE
- Where
- 5 sites in United States
- Volunteers
- 8 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc)
Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer
The purpose of this study is to evaluate the anti-tumor efficacy of daraxonrasib monotherapy in patients with unresectable or advanced/metastatic, KRAS-mutant BTC who have progressed on or are intolerant of 1st line systemic…
- Conditions
- Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc), Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma
- Trial name
- NCT07793253
- Testing
- Daraxonrasib
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma
This is a two arm, open label, multi-center, Phase 2 study to evaluate the efficacy and safety of Melphalan/HDS in patients with unresectable Hepatocellular Carcinoma (HCC) or Intra Hepatic Cholangiocarcinoma (ICC) confined to…
- Trial name
- NCT02415036
- Testing
- Delcath Hepatic Delivery System, Melphalan
- Where
- 3 sites in Germany
- Volunteers
- 17 people
- Sponsor
- Delcath Systems Inc.
Cholangiocarcinoma
HAIC Combined With Donafenib and Sintilimab for Unresectable ICC
To evaluate the safety and tolerability of HAIC combined with donafenib and sintilimab in first-line treatment of unresectable ICC.
- Trial name
- NCT05348811
- Testing
- HAIC combined with donafenib and sintilimab
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Zhongda Hospital